Abiopharma

New Form 4/A - P3 Health Partners Inc. Filed: 2026-01-23 AccNo: 0001232914-26-000002 Size: 5 KB

New Form 4/A - P3 Health Partners Inc. Filed: 2026-01-23 AccNo: 0001188827-26-000002 Size: 6 KB

New Form 4/A - P3 Health Partners Inc. Filed: 2026-01-23 AccNo: 0001492118-26-000001 Size: 5 KB

New Form 4/A - P3 Health Partners Inc. Filed: 2026-01-23 AccNo: 0001334925-26-000001 Size: 6 KB

New Form 4/A - P3 Health Partners Inc. Filed: 2026-01-23 AccNo: 0001406618-26-000003 Size: 5 KB

New Form 4/A - P3 Health Partners Inc. Filed: 2026-01-23 AccNo: 0001804153-26-000001 Size: 5 KB

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

New Form 424B3 - TRINITY BIOTECH PLC Filed: 2026-01-23 AccNo: 0001178913-26-000212 Size: 179 KB

New Form 3 - STAAR SURGICAL CO Filed: 2026-01-23 AccNo: 0001213900-26-007316 Size: 5 KB

Nexalin Technology Receives Nasdaq Listing Status Notification

Nexalin Technology Receives Nasdaq Listing Status Notification

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

CNEY Receives Nasdaq Delisting Determination for Minimum Bid Price Deficiency

UTHR: Notification

UTHR: Notification